Literature DB >> 27783090

Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant.

Joseph D Boss, Kevin Rosenberg, Rajiv Shah.   

Abstract

Resistant strains of cytomegalovirus can be difficult to treat in cases of congenital cytomegalovirus retinitis. The authors describe a case of recurrent bilateral congenital cytomegalovirus retinitis in an immunocompetent newborn with ganciclovir resistance successfully treated uniquely with dual therapy of intravenous ganciclovir and foscarnet and dual intravitreal injections with ganciclovir and foscarnet. [J Pediatr Ophthalmol Strabismus. 2016;53:e58-e60.]. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27783090     DOI: 10.3928/01913913-20161003-02

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis.

Authors:  Jing-Jing Fan; Yong Tao; De-Kuang Hwang
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

2.  Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study.

Authors:  Yuka Torii; Kazuhiro Horiba; Jun-Ichi Kawada; Kazunori Haruta; Makoto Yamaguchi; Takako Suzuki; Hideko Uryu; Naoyuki Kashiwa; Keiji Goishi; Tomoo Ogi; Yoshinori Ito
Journal:  BMC Infect Dis       Date:  2022-06-22       Impact factor: 3.667

3.  Clinical efficacy of laser therapy in the prevention of retinal detachment in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

Authors:  Lian-Yong Xie; Xiao-Na Li; Chao Chen; Wen-Jun Kong; Tai-Yi Jiang; Kui-Fang Du; Hong-Wei Dong; Chun-Gang Guo; Wen-Bin Wei
Journal:  Quant Imaging Med Surg       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.